Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Target deconvolution strategies in drug discovery

Key Points

  • In this postgenomic era, the perceived 'failure' of target-based drug discovery (in part owing to the complexities of biological systems and disease pathophysiology) has recently led to the renaissance of a more holistic approach that involves screening small organic molecules to determine whether they elicit any phenotypic changes in mammalian cells and model organisms.

  • The retrospective identification of the molecular targets that underlie observed phenotypic responses — termed target deconvolution — is important for elucidating biological mechanisms of disease and will also greatly aid rational drug design and enable efficient structure–activity relationship studies to be carried out in a chemical optimization programme by configuration of target-specific assays.

  • A wide range of experimental strategies can in principle be applied to the identification of targets that mediate phenotypic effects. The choice will often mainly be influenced by the properties of the small molecule.

  • Methods that lead to the direct identification of targets typically exploit the affinity between the small organic molecule and its target protein. These methods include affinity chromatography, three-hybrid systems, phage and mRNA display, protein and 'reverse-transfected' cell microarrays, and biochemical suppression.

  • Methods that are based on comprehensive DNA microarray or proteomics analyses can aid target deconvolution because they investigate the mode of action of an active small molecule. In a more indirect way, these technologies can also lead to the identification of molecular targets.

  • The final aim of target deconvolution is not only the identification of biological targets that directly interact with the small molecule, but also the demonstration that the target's modulation is associated with functional effects that are detectable in the phenotypic assay. The 'authenticity' of targets can be confirmed by functional studies that employ a variety of methods, such as RNA interference and protein overexpression.

  • Since phenotype-based drug discovery regained momentum, target deconvolution has become an important aspect of current drug discovery.

Abstract

Recognition of some of the limitations of target-based drug discovery has recently led to the renaissance of a more holistic approach in which complex biological systems are investigated for phenotypic changes upon exposure to small molecules. The subsequent identification of the molecular targets that underlie an observed phenotypic response — termed target deconvolution — is an important aspect of current drug discovery, as knowledge of the molecular targets will greatly aid drug development. Here, the broad panel of experimental strategies that can be applied to target deconvolution is critically reviewed.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Phenotype-based versus target-based drug discovery.
Figure 2: Affinity-chromatography-based methods for target deconvolution.
Figure 3: Three-hybrid systems for target deconvolution.
Figure 4: Display technologies for target deconvolution.
Figure 5: Microarray technologies for target deconvolution.
Figure 6: Biochemical suppression in target deconvolution.

References

  1. 1

    Sneader, W. Drug discovery: a history (John Wiley & Sons, Chichester, UK, 2005).

    Book  Google Scholar 

  2. 2

    International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931–945 (2004).

  3. 3

    Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).

    CAS  Article  Google Scholar 

  4. 4

    Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).

    CAS  Article  Google Scholar 

  5. 5

    Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006). This study examines the results of a comprehensive survey and proposes a consensus number of current drug targets for all classes of therapeutic drugs.

    CAS  Article  Google Scholar 

  6. 6

    Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discov. Today 10, 139–147 (2005).

    CAS  Article  Google Scholar 

  7. 7

    Butcher, E. C. Can cell systems biology rescue drug discovery? Nature Rev. Drug Discov. 4, 461–467 (2005).

    CAS  Article  Google Scholar 

  8. 8

    Strausberg, R. L. & Schreiber, S. L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294–295 (2003).

    CAS  Article  Google Scholar 

  9. 9

    Graziani, F., Aldegheri, L. & Terstappen, G. C. High throughput scintillation proximity assay for the identification of FKBP-12 ligands. J. Biomol. Screen. 4, 3–7 (1999).

    CAS  Article  Google Scholar 

  10. 10

    Caligiuri, M. et al. MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule–protein interactions in mammalian cells. Chem. Biol. 13, 711–722 (2006). This paper describes the application of methotrexate-linked small-molecule ligands to the configuration of a mammalian three-hybrid interaction trap for the proteome-wide identification of small molecule targets.

    CAS  Article  Google Scholar 

  11. 11

    Harding, M. W., Galat, A., Uehling, D. E. & Schreiber, S. L. A receptor for the immunosuppressant FK506 is a cistrans peptidyl-prolyl isomerase. Nature 341, 758–760 (1989).

    CAS  Article  Google Scholar 

  12. 12

    Licitra, E. J. & Liu, J. O. A three-hybrid system for detecting small ligand–protein receptor interactions. Proc. Natl Acad. Sci. USA 93, 12817–12821 (1996). This study demonstrates that a yeast three-hybrid system can be used to discover receptors for small ligands.

    CAS  Article  Google Scholar 

  13. 13

    MacBeath, G. & Schreiber, S. L. Printing proteins as microarrays for high-throughput function determination. Science 289, 1760–1763 (2000). This study demonstrates that protein microarrays can be used for the identification of protein targets of small molecules.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14

    McPherson, M., Yang, Y., Hammond, P. W. & Kreider, B. L. Drug receptor identification from multiple tissues using cellular-derived mRNA display libraries. Chem. Biol. 9, 691–698 (2002). This proof-of-concept study demonstrates that mRNA display technology can be used to select proteins that bind to a drug of interest.

    CAS  Article  Google Scholar 

  15. 15

    Sche, P. P., McKenzie, K. M., White, J. D. & Austin, D. J. Display cloning: functional identification of natural product receptors using cDNA-phage display. Chem. Biol. 6, 707–716 (1999).

    CAS  Article  Google Scholar 

  16. 16

    Siekierka, J. J., Hung, S. H., Poe, M., Lin, C. S. & Sigal, N. H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341, 755–757 (1989).

    CAS  Article  Google Scholar 

  17. 17

    Ziauddin, J. & Sabatini, D. M. Microarrays of cells expressing defined cDNAs. Nature 411, 107–110 (2001). This paper demonstrates the feasibility of using reverse-transfected cell microarrays for the identification of drug targets.

    CAS  Article  Google Scholar 

  18. 18

    Cuatrecasas, P. Affinity chromatography and purification of the insulin receptor of liver cell membranes. Proc. Natl Acad. Sci. USA 69, 1277–1281 (1972).

    CAS  Article  Google Scholar 

  19. 19

    Taunton, J., Hassig, C. A. & Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408–411 (1996).

    CAS  Article  Google Scholar 

  20. 20

    Guiffant, D. et al. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol. J. 2, 68–75 (2007).

    CAS  Article  Google Scholar 

  21. 21

    Laing, P. Luminescent visualization of antigens on blots. J. Immunol. Methods 92, 161–165 (1986).

    CAS  Article  Google Scholar 

  22. 22

    Bennett, K. L., Brond, J. C., Kristensen, D. B., Podtelejnikov, A. V. & Wisniewski, J. R. Analysis of large-scale MS data sets: the dramas and the delights. Drug Discov. Today: TARGETS 3 (Suppl. 1), 43–49 (2005).

    Google Scholar 

  23. 23

    Schuchardt, S. & Sickmann, A. Protein identification using mass spectrometry: a method overview. EXS 97, 141–170 (2007).

    CAS  PubMed  Google Scholar 

  24. 24

    Yates, J. R. III. Mass spectrometry and the age of the proteome. J. Mass Spectrom. 33, 1–19 (1998).

    CAS  Article  Google Scholar 

  25. 25

    Hahn, R., Berger, E., Pflegerl, K. & Jungbauer, A. Directed immobilization of peptide ligands to accessible pore sites by conjugation with a placeholder molecule. Anal. Chem. 75, 543–548 (2003).

    CAS  Article  Google Scholar 

  26. 26

    Shaltiel, S. Hydrophobic chromatography. Methods Enzymol. 104, 69–96 (1984).

    CAS  Article  Google Scholar 

  27. 27

    Shiyama, T., Furuya, M., Yamazaki, A., Terada, T. & Tanaka, A. Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. Bioorg. Med. Chem. 12, 2831–2841 (2004).

    CAS  Article  Google Scholar 

  28. 28

    Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208–31219 (2005).

    CAS  Article  Google Scholar 

  29. 29

    Sato, S. et al. Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. J. Am. Chem. Soc. 129, 873–880 (2007).

    CAS  Article  Google Scholar 

  30. 30

    Godl, K. et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl Acad. Sci. USA 100, 15434–15439 (2003).

    CAS  Article  Google Scholar 

  31. 31

    Emami, K. H. et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc. Natl Acad. Sci. USA 101, 12682–12687 (2004).

    CAS  Article  Google Scholar 

  32. 32

    Snyder, J. R. et al. Dissection of melanogenesis with small molecules identifies prohibitin as a regulator. Chem. Biol. 12, 477–484 (2005).

    CAS  Article  Google Scholar 

  33. 33

    Wang, G., Shang, L., Burgett, A. W., Harran, P. G. & Wang, X. Diazonamide toxins reveal an unexpected function for ornithine δ-amino transferase in mitotic cell division. Proc. Natl Acad. Sci. USA 104, 2068–2073 (2007).

    CAS  Article  Google Scholar 

  34. 34

    Shimizu, N. et al. High-performance affinity beads for identifying drug receptors. Nature Biotech. 18, 877–881 (2000).

    CAS  Article  Google Scholar 

  35. 35

    Labrou, N. & Clonis, Y. D. The affinity technology in downstream processing. J. Biotechnol. 36, 95–119 (1994).

    CAS  Article  Google Scholar 

  36. 36

    Graves, P. R. et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–1372 (2002).

    CAS  Article  Google Scholar 

  37. 37

    Oda, Y. et al. Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 75, 2159–2165 (2003).

    CAS  Article  Google Scholar 

  38. 38

    Yamamoto, K., Yamazaki, A., Takeuchi, M. & Tanaka, A. A versatile method of identifying specific binding proteins on affinity resins. Anal. Biochem. 352, 15–23 (2006).

    CAS  Article  Google Scholar 

  39. 39

    Fields, S. & Song, O. A novel genetic system to detect protein–protein interactions. Nature 340, 245–246 (1989).

    CAS  Article  Google Scholar 

  40. 40

    Becker, F. et al. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol. 11, 211–223 (2004).

    CAS  Article  Google Scholar 

  41. 41

    Gray, N. S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533–538 (1998).

    CAS  Article  Google Scholar 

  42. 42

    Knockaert, M. et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 7, 411–422 (2000).

    CAS  Article  Google Scholar 

  43. 43

    Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44

    Wisniewski, D. et al. Characterization of potent inhibitors of the Bcr–Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62, 4244–4255 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45

    Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).

    CAS  Article  Google Scholar 

  46. 46

    Rossenu, S., Dewitte, D., Vandekerckhove, J. & Ampe, C. A phage display technique for a fast, sensitive, and systematic investigation of protein–protein interactions. J. Protein Chem. 16, 499–503 (1997).

    CAS  Article  Google Scholar 

  47. 47

    Shim, J. S., Lee, J., Park, H. J., Park, S. J. & Kwon, H. J. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem. Biol. 11, 1455–1463 (2004).

    CAS  Article  Google Scholar 

  48. 48

    Mattheakis, L. C., Bhatt, R. R. & Dower, W. J. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl Acad. Sci. USA 91, 9022–9026 (1994). This paper describes an in vitro protein synthesis system for the construction of large libraries of peptides displayed on polysomes (mRNA display).

    CAS  Article  Google Scholar 

  49. 49

    Hammond, P. W., Alpin, J., Rise, C. E., Wright, M. & Kreider, B. L. In vitro selection and characterization of Bcl-XL-binding proteins from a mix of tissue-specific mRNA display libraries. J. Biol. Chem. 276, 20898–20906 (2001).

    CAS  Article  Google Scholar 

  50. 50

    Zhu, H. & Snyder, M. Protein chip technology. Curr. Opin. Chem. Biol. 7, 55–63 (2003).

    CAS  Article  Google Scholar 

  51. 51

    Jacinto, E. & Hall, M. N. Tor signalling in bugs, brain and brawn. Nature Rev. Mol. Cell Biol. 4, 117–126 (2003).

    CAS  Article  Google Scholar 

  52. 52

    Huang, J. et al. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl Acad. Sci. USA 101, 16594–16599 (2004).

    CAS  Article  Google Scholar 

  53. 53

    Peterson, J. R., Lebensohn, A. M., Pelish, H. E. & Kirschner, M. W. Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. Chem. Biol. 13, 443–452 (2006). This paper introduces a target deconvolution method that is based on functional suppression of chemical inhibition in vitro.

    CAS  Article  Google Scholar 

  54. 54

    Mayer, T. U. Chemical genetics: tailoring tools for cell biology. Trends Cell Biol. 13, 270–277 (2003).

    CAS  Article  Google Scholar 

  55. 55

    Giaever, G. et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl Acad. Sci. USA 101, 793–798 (2004).

    CAS  Article  Google Scholar 

  56. 56

    Li, X. et al. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem. Biol. 11, 1423–1430 (2004).

    CAS  Article  Google Scholar 

  57. 57

    Luesch, H. et al. A genome-wide overexpression screen in yeast for small-molecule target identification. Chem. Biol. 12, 55–63 (2005).

    CAS  Article  Google Scholar 

  58. 58

    Gonzalez-Couto, E. et al. Huntington's disease: from experimental results to interaction networks, patho-pathway construction and disease hypothesis. BMC Syst. Biol. 1, 45–47 (2007).

    Article  Google Scholar 

  59. 59

    Ekins, S., Nikolsky, Y., Bugrim, A., Kirillov, E. & Nikolskaya, T. Pathway mapping tools for analysis of high content data. Methods Mol. Biol. 356, 319–350 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. 60

    Macchiarulo, A., Nobeli, I. & Thornton, J. M. Ligand selectivity and competition between enzymes in silico. Nature Biotech. 22, 1039–1045 (2004).

    CAS  Article  Google Scholar 

  61. 61

    Mueller, M., Martens, L. & Apweiler, R. Annotating the human proteome: beyond establishing a parts list. Biochim. Biophys. Acta 1774, 175–191 (2007).

    CAS  Article  Google Scholar 

  62. 62

    Kramer, R. & Cohen, D. Functional genomics to new drug targets. Nature Rev. Drug Discov. 3, 965–972 (2004).

    CAS  Article  Google Scholar 

  63. 63

    Flordellis, C. S., Manolis, A. S., Paris, H. & Karabinis, A. Rethinking target discovery in polygenic diseases. Curr. Top. Med. Chem. 6, 1791–1798 (2006).

    CAS  Article  Google Scholar 

  64. 64

    Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).

    CAS  Article  Google Scholar 

  65. 65

    Hu, L., Xu, S., Pan, C., Zou, H. & Jiang, G. Preparation of a biochip on porous silicon and application for label-free detection of small molecule–protein interactions. Rapid Commun. Mass Spectrom. 21, 1277–1281 (2007).

    CAS  Article  Google Scholar 

  66. 66

    Zhang, Q. et al. Small-molecule synergist of the Wnt/β-catenin signaling pathway. Proc. Natl Acad. Sci. USA 104, 7444–7448 (2007).

    CAS  Article  Google Scholar 

  67. 67

    Carroll, P. M. & Fitzgerald, K. Model Organisms in Drug Discovery (Culinary and Hospitality Industry Publications Services, Texas, 2003).

    Book  Google Scholar 

  68. 68

    Clemons, P. A. Complex phenotypic assays in high-throughput screening. Curr. Opin. Chem. Biol. 8, 334–338 (2004).

    CAS  Article  Google Scholar 

  69. 69

    Gangadhar, N. M. & Stockwell, B. R. Chemical genetic approaches to probing cell death. Curr. Opin. Chem. Biol. 11, 83–87 (2007).

    CAS  Article  Google Scholar 

  70. 70

    Caricasole, A. et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci. 24, 6021–6027 (2004).

    CAS  Article  Google Scholar 

  71. 71

    Barker, N. & Clevers, H. Mining the Wnt pathway for cancer therapeutics. Nature Rev. Drug Discov. 5, 997–1014 (2006).

    CAS  Article  Google Scholar 

  72. 72

    Lang, P., Yeow, K., Nichols, A. & Scheer, A. Cellular imaging in drug discovery. Nature Rev. Drug Discov. 5, 343–356 (2006).

    CAS  Article  Google Scholar 

  73. 73

    Ignatenko, N. A. et al. Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161. Technol. Cancer Res. Treat. 5, 553–564 (2006).

    CAS  Article  Google Scholar 

  74. 74

    Lamb, J. et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006). This paper is the first installment of a reference collection of gene-expression profiles from cultured human cells that were treated with 164 bioactive small molecules.

    CAS  Article  Google Scholar 

  75. 75

    Nature Insight Proteomics. [online] (2003).

  76. 76

    Raggiaschi, R. & Terstappen G. C. Proteomics technologies. Biosci. Rep. 25, 1–2 (2005).

    CAS  Article  Google Scholar 

  77. 77

    Kremer, A., Schneider, R. & Terstappen, G. C. A bioinformatics perspective on proteomics: data storage, analysis, and integration. Biosci. Rep. 25, 95–106 (2005).

    CAS  Article  Google Scholar 

  78. 78

    Towbin, H. et al. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors. J. Biol. Chem. 278, 52964–52971 (2003).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Georg C. Terstappen.

Related links

Related links

DATABASES

Medscape

indomethacin

methotrexate

Glossary

Rational drug design

A strategy by which drug molecules are developed based on knowledge of the target protein, in particular its three-dimensional structure and/or the ligands that bind to it.

Structure–activity relationship studies

Studies in which the chemical structure of a bioactive small molecule is modified (for example, by insertion of new chemical groups) to investigate the effect of this modification on the molecule's biological activity. The aim of such studies in a chemical optimization programme is typically to improve the characteristics of the compound, such as its potency and selectivity.

FK506–FKBP12

FK506 (also known as Tacrolimus or Fujimycin) is an immunosuppressant organic molecule that binds to the immunophilin FKBP12 (FK506 binding protein 12 kDa), which functions as a protein-folding chaperone for proteins that contain proline residues. Owing to the high affinity between FK506 and FKBP12 (with a dissociation constant of 1.6 nM) and the high cellular abundance of the latter, this pair is often used as a model system for proof-of-concept experiments of affinity-based technologies.

Dissociation constant

(kD). A measure of the affinity of a ligand (for example, a small molecule) for a protein. Its numerical value depends on the equilibrium between the undissociated and the dissociated forms of the molecular complex. The smaller the dissociation constant, the tighter the ligand is bound (or the higher its affinity for the target protein).

Biotinylation

The derivatization of molecules with the small organic molecule biotin (also known as vitamin H or vitamin B7). Biotinylation enables molecules to bind to streptavidin with high affinity (with a dissociation constant of 10−15 M) — a property that has widespread applications in biotechnology.

cDNA library

A library comprised of cDNAs that are obtained when mRNA is extracted from a cell and reverse transcribed. The library thus represents all transcribed sequences and hence all proteins that the cell was expressing.

Sequence-similarity search

A type of search that provides information about how one nucleotide or protein sequence is related to another. The similarity between the two sequences is expressed as a percentage of sequence identity, and can be used to identify a target protein. Typically, pairwise sequence-search methods such as BLAST and FASTA are used.

Reporter gene assay

An assay that is used to investigate the modulation of a signal transduction pathway. An easily detectable reporter gene, such as luciferase, is fused to the promoter sequence of downstream target genes of the pathway under study; modulation of the pathway, such as activation or inhibition, will lead to changes in reporter gene expression (in the case of luciferase, these changes will be measured as luminescence).

Matrix-assisted laser desorption/ionization mass spectrometry

(MALDI-MS). An analytical technique that is often used to identify biomolecules such as proteins after they have (typically) been isolated by gel electrophoresis.

DNA microarray analysis

A technique that uses DNA microarrays (gene chips) to investigate the expression of thousands of genes or of a complete genome in parallel. DNA molecules are immobilized on a solid support, then labelled nucleotides are hybridized to their complementary sequences and their signals are detected.

Haploinsufficiency profiling

A chemical genomics assay that uses a heterozygous yeast deletion strain in which the gene dosage is reduced to one copy, resulting in a strain that is sensitized to compounds that inhibit the product of the heterozygous locus.

Surface plasmon resonance

An optical biosensor technology that measures the association (kA) and dissociation (kD) constants of interactions in a label-free manner. The small-molecule ligand is immobilized onto the surface of a sensor chip and any interaction with the putative target protein will lead to an increase in the refractive index, which is measured in real time.

Resonance acoustic profiling

A technology that characterizes molecular binding interactions through the use of oscillating acoustic resonators. Any interaction between a small molecule and its target protein is directly detected by resonating quartz crystals.

RNA interference

A method for silencing gene expression. A small double-stranded RNA is introduced into the cell to inhibit the expression of the corresponding mRNA, thus preventing translation of the gene into protein.

Polypharmacologic compounds

Compounds that bind to multiple cellular targets to mediate their clinical effects.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Terstappen, G., Schlüpen, C., Raggiaschi, R. et al. Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 6, 891–903 (2007). https://doi.org/10.1038/nrd2410

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing